Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer
作者： Nataša Todorović-Raković , Danica Jovanović , Zora Nešković-Konstantinović , Dragica Nikolić-Vukosavljević
DOI: 10.1016/J.YEXMP.2007.01.002
关键词:
摘要: After so many years of research, clinical value HER2 (Human epidermal growth factor receptor 2) is unclear. Perhaps the main reason variability testing methods that produce controversial results. There a lack studies regarding prognostic CISH especially in metastatic breast cancer (MBC) when risk evaluation based on different parameters than for primary cancer. Aim this study was to compare relevance status MBC tested by two i.e. immunohistochemistry (IHC) and chromogenic situ hybridization (CISH). same group 107 patients determined IHC (protein overexpression) (gene amplification). results obtained showed significant correlation, beside existence discrepancies. Beside correlation methods, there difference values compared during course disease. progression-free interval (PFI) between non-amplified amplified cases CISH, postmenopausal subgroup node-positive subgroup, but no stratified patients. seems be accurate more informative method
elsevier.com
sci-hub.se 参考文章(34)
I Ellis, W.J Gullick, B Gusterson, E Mallon, R Walker, M Dowsett, T Cooke, Assessment of HER2 status in breast cancer: why, when and how? European Journal of Cancer. ,vol. 36, pp. 170- 176 ,(2000) , 10.1016/S0959-8049(99)00264-6
Manuelito A Madrid, Raymundo W Lo, Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/ neu status Breast Cancer Research. ,vol. 6, pp. 1- 8 ,(2004) , 10.1186/BCR915
Godolphin W, Pauletti G, Press Mf, Slamon Dj, Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. ,vol. 13, pp. 63- 72 ,(1996)
Marcus Schmidt, Barbara Lewark, Nikolai Kohlschmidt, Christiane Glawatz, Erik Steiner, Berno Tanner, Henryk Pilch, Wolfgang Weikel, Heinz Kölbl, Hans-Anton Lehr, None, Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing Breast Cancer Research. ,vol. 7, pp. 1- 11 ,(2005) , 10.1186/BCR991
Mårten Fernö, Åke Borg, Bo Baldetorp, Dick Killander, Håkan Olsson, H Sigurdsson, ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene. ,vol. 6, pp. 137- 143 ,(1991)
William L. McGuire, Gary M. Clark, Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Research. ,vol. 51, pp. 944- 948 ,(1991)
Lauren Hammock, Melinda Lewis, Carol Phillips, Cynthia Cohen, Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization1 1This manuscript consists of original material not previously accepted for publication by another journal. The manuscript does not include use of any investigational or “off-label” products. The authors do not have a financial or other relationship with any of the commercial enterprises whose products or services may be discussed in this original article. Human Pathology. ,vol. 34, pp. 1043- 1047 ,(2003) , 10.1053/S0046-8177(03)00409-X
Michael F. Press, Dennis J. Slamon, Kerry J. Flom, Jinha Park, Jian-Yuan Zhou, Leslie Bernstein, Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens Journal of Clinical Oncology. ,vol. 20, pp. 3095- 3105 ,(2002) , 10.1200/JCO.2002.09.094
Luis Alberto Rubio-Martinez, José Maria Vera-Roman, Comparative assays for the HER-2/neu oncogene status in breast cancer. Archives of Pathology & Laboratory Medicine. ,vol. 128, pp. 627- 633 ,(2004) , 10.1043/1543-2165(2004)128<627:CAFTNO>2.0.CO;2
R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, T.M. Grogan, Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message Journal of Clinical Oncology. ,vol. 19, pp. 2714- 2721 ,(2001) , 10.1200/JCO.2001.19.10.2714